acquired
Stage
About
Adnexus Therapeutics developed Adnectins, a class of biologic therapeutics derived from human fibronectin, and advanced biologic and antibody drug candidates for disease treatment. Founded in 2003, the company was acquired by Bristol-Myers Squibb in 2007.
Explore Adnexus Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.